Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | 50 | 14.07.21 | |
Director of Finance/CFO | 69 | 11.01. | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 15.01.21 |
Doug Randall
COO | Chief Operating Officer | - | 14.11.13 |
Douglas Hay
LAW | General Counsel | - | 14.11.13 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 04.04.14 |
June Almenoff
BRD | Director/Board Member | 67 | 25.02.21 |
Declan Doogan
BRD | Director/Board Member | 72 | 25.02.21 |
Michael Davidson
BRD | Director/Board Member | 67 | 25.02.21 |
Robyn Hunter
BRD | Director/Board Member | 62 | 28.01.22 |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 15.01.21 |
Chief Executive Officer | 50 | 14.07.21 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 0 | 210 | 0 | 0 | 99,65 % |
Aktie B | 1 | 1 958 245 | 1 951 297 ( 99,65 %) | 0 |
Unternehmenskontakt
Tenax Therapeutics, Inc.
101 Glen Lennox Drive Suite 300
27517, Chapel Hill
+(919) 855-2100
http://www.tenaxthera.com![Straße Tenax Therapeutics Inc](https://cdn.zonebourse.com/static/address/18045260.png)
Sektor
% 1. Jan. | Kap. | |
---|---|---|
+38,36 % | 52,73 Mrd. | |
+36,73 % | 39 Mrd. | |
-8,63 % | 38,52 Mrd. | |
+25,46 % | 30,38 Mrd. | |
-11,17 % | 26,39 Mrd. | |
+11,44 % | 26,08 Mrd. | |
+45,09 % | 14,15 Mrd. | |
+32,93 % | 12,6 Mrd. | |
-5,30 % | 11,51 Mrd. |